Article: Mind the Skills Gap
“There’s a little over 1,200 clinical trials worldwide, and about half of those are in the US. Over 100 of those are in phase III, so we’re getting really close to getting more approved.”
ISPE Guide: ATMPs – Autologous Cell Therapy
Project Farma experts Lesley Davis, Andrew Doppstadt, and Phil Baratta recently participated in the publication of an ISPE Guide titled, “Advanced Therapy Medicinal Products – Autologous Cell Therapy”.
Article: Mind the Cell & Gene Gap
A 2018 study by Deloitte suggested that more than 2.4 million manufacturing jobs in the US would remain unfilled in 2028 because of the widening – and often generational – skills gap.
On-Demand Webinar: CQV Strategies that Increase Speed-to-Market for Gene Therapy
To successfully increase speed-to-market for gene therapies, having a defined CQV (Commissioning, Qualification, and Validation) strategy is critical to project success. In this webinar co-sponsored by Precision ADVANCE and Project Farma, our panel of industry experts discuss tips for delivering efficient, reliable, GMP-compliant facilities and processes specific to gene therapy.
On-Demand Webinar: State of the Union for Advanced Medicines
We are in the midst of a therapeutic revolution. An H1 report released by Alliance for Regenerative Medicine (ARM) highlights a record-breaking year, with over 1,320 ongoing clinical trials worldwide and 1000+ therapeutic developers. As 2021 comes to an end, we are on track to expect the highest number of advanced therapy regulatory approvals, when compared to previous years.